REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for REFRACTORY ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising Three-Drug cocktail targets tough leukemia
Disease control Not yet recruitingThis study tests a new combination of three drugs (aclarubicin, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML), including those newly diagnosed or whose cancer has returned. The goal is to find the safest dose and see if the combo helps control the dise…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CD64 CAR T cells for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, mod…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 14, 2026 12:04 UTC